TY - JOUR
T1 - What Lies Beneath the Face Value of a BOX WARNING
T2 - A Deeper Look at Brodalumab
AU - Hashim, Peter W.
AU - Chen, Tinley
AU - Lebwohl, Mark G.
AU - Marangell, Lauren B.
AU - Kircik, Leon H.
PY - 2018/8/1
Y1 - 2018/8/1
N2 - Brodalumab, a fully human antibody of the interleukin-17 receptor, is highly effective in the treatment of moderate-to-severe plaque psoriasis. However, based on safety signals identified in clinical trials, brodalumab carries a boxed warning regarding possible risks of suicidal ideation and behavior (SIB). The validity of this link remains controversial, especially in the context of the psoriasis population as well as clinical trial data from other recently approved treatments. Herein, we critically examine the association between brodalumab and SIB. J Drugs Dermatol. 2018;17(8 Suppl):s29-34.
AB - Brodalumab, a fully human antibody of the interleukin-17 receptor, is highly effective in the treatment of moderate-to-severe plaque psoriasis. However, based on safety signals identified in clinical trials, brodalumab carries a boxed warning regarding possible risks of suicidal ideation and behavior (SIB). The validity of this link remains controversial, especially in the context of the psoriasis population as well as clinical trial data from other recently approved treatments. Herein, we critically examine the association between brodalumab and SIB. J Drugs Dermatol. 2018;17(8 Suppl):s29-34.
UR - https://www.scopus.com/pages/publications/85056657773
M3 - Review article
C2 - 30124737
AN - SCOPUS:85056657773
SN - 1545-9616
VL - 17
SP - s29-s34
JO - Journal of Drugs in Dermatology
JF - Journal of Drugs in Dermatology
IS - 8
ER -